• 1
    Chen CL, Fan ST, Lee SG, Makuuchi M, Tanaka K. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation 2003; 75: S6-11.
  • 2
    Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002; 346: 1074-1082.
  • 3
    Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998; 66: 59-66.
  • 4
    Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
  • 5
    Chuang FR, Lee CH, Chien YS, Chen YS, Chen CL. Acute renal failure after living-related liver transplantation. Transplant Proc 2003; 35: 429-430.
  • 6
    Lin CC, Chuang FR, Wang CC, Chen YS, Chen CL, Liu YW, et al. Early postoperative complications in living donor liver transplantation recipients. Transplant Proc 2004; 36: 2338-2341.
  • 7
    Porayko MK, Gonwa TA, Klintmalm GB, Wiesner RH. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from U.S. Multicenter trial. U.S. Multicenter Liver Study Group. Transplant Proc 1995; 27: 1114-1116.
  • 8
    Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193-1198.
  • 9
    Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. CHIC 304 International Liver Study Group. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132-142.
  • 10
    Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002; 8: 123-131.
  • 11
    Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69: 307-311.
  • 12
    de Villa VH, Chen CL, Chen YS, Wang CC, Lin CC, Cheng YF, et al. Right lobe living donor liver transplantation—addressing the middle hepatic vein controversy. Ann Surg 2003; 238: 275-282.
  • 13
    Chen CL, Chen YS, de Villa VH, Wang CC, Lin CL, Goto S, et al. Minimal blood loss living donor hepatectomy. Transplantation 2000; 69: 2580-2586.
  • 14
    Huang CJ, Chen CL, Tseng CC, Luk HN, De Villa V, Wang CS, et al. Maintenance of normothermia at operation room temperature of 24°C in adult and pediatric patients undergoing liver transplantation. Transplant Int 2005; 18: 396-400.
  • 15
    Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334: 1448-1460.
  • 16
    AlDosary AA, Ramji AS, Elliott TG, Sirrs SM, Thompson DM, Erb SR, et al. Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl 2002; 8: 356-361.
  • 17
    Bismuth H, Castating D, Sherock D. Liver transplantation by face-a-face venacavaplasty. Surgery 1992; 111: 151-155.
  • 18
    Raimondo ML, Dagher L, Papatheodoridis GV, Rolando N, Patch DW, Davidson BR, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003; 75: 186-190.
  • 19
    Korelitz BI, Present DH. Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial. Gastroenterology 1981; 80: 193-196.
  • 20
    Cantarovich M, Metrakos P, Giannetti N, Cecere R, Barkun J, Tchervenkov J. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor “holiday” in solid organ transplant patients with acute renal dysfunction. Transplantation 2002; 73: 1169-1172.
  • 21
    Kovarik JM, Kahan BD, Rajagopalan PR, Bennett W, Mulloy LL, Gerbeau C, Hall ML. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation 1999; 68: 1288-1294.
  • 22
    Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69: 1867-1872.
  • 23
    Heffron TG, Pillen T, Smallwood GA, Welch D, Oakley B, Romero R. Pediatric liver transplantation with daclizumab induction. Transplantation 2003; 75: 2040-2043.
  • 24
    Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, Wong J. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004; 10: 728-733.
  • 25
    Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901-906.